Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial

被引：0
|
作者：
Johnson, DH
Paul, D
Hande, KR
机构：
来源：
SEMINARS IN ONCOLOGY | 1997年 / 24卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S22 / S25
页数：4
相关论文
共 50 条
  • [31] L-FOLINIC ACID AND 5-FLUOROURACIL IN THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II STUDY
    ZANIBONI, A
    MERIGGI, F
    ARCANGELI, G
    MARPICATI, P
    MONTINI, E
    SIMONCINI, E
    MARINI, G
    ANNALS OF ONCOLOGY, 1993, 4 : S41 - S43
  • [32] Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: A phase I study
    Cortesi, E
    Grifalchi, F
    Ramponi, S
    Padovani, A
    Mancuso, A
    Paoluzzi, L
    Ferrau, F
    Oliva, A
    ANTICANCER RESEARCH, 2003, 23 (2C) : 1961 - 1966
  • [33] Phase I/II study of paclitaxel and 5-fluorouracil as second-line therapy in patients with metastatic breast cancer
    Gleissner, B
    Hellmann, A
    Berdel, WE
    Edler, L
    Koldehoff, M
    Rost, A
    Opri, F
    Fritze, D
    Öhl, S
    ONKOLOGIE, 1998, 21 (04): : 305 - 308
  • [34] Phase II evaluation of 5-fluorouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer
    Kohne, CH
    Wilke, H
    Hiddemann, W
    Bokemeyer, C
    Lohrmann, HP
    Bodenstein, H
    Preiss, J
    Rauschecker, H
    Hill, H
    Kaufer, C
    Fischer, JT
    Ohl, U
    Urbanitz, D
    Balleisen, L
    Schmoll, HJ
    ONCOLOGY, 1997, 54 (02) : 96 - 101
  • [35] Phase III trial of carboplatin, etoposide and paclitaxel compared with 5-fluorouracil and folinic acid in adenocarcinoma of unknown primary.
    van De Wouw, A
    Hillen, HFP
    van der Heul, C
    van Hoesel, R
    Jansen, RLH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 881S - 881S
  • [36] The combination of 5-fluorouracil and folinic acid in the treatment of breast cancer: The emerging role
    Zaniboni, A
    CANCER JOURNAL - FRANCE, 1996, 9 (02): : 77 - 78
  • [37] Phase II trial of cisplatin (CDDP), 5-Fluorouracil (5Fu) and folinic acid (FA) for relapsing or metastatic squamous cell cancer of the head and neck (SCCHN)
    Vaz, F
    Oliveira, J
    Ferreira, M
    Torrinha, F
    Fernandes, A
    ANNALS OF ONCOLOGY, 1998, 9 : 79 - 79
  • [38] Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil - A prospective cohort study
    Moehler, M
    Gutzler, F
    Steinmann, S
    Boehme, M
    Raeth, U
    Stremmel, W
    Galle, PR
    Rudi, J
    CHEMOTHERAPY, 2003, 49 (1-2) : 85 - 89
  • [39] A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer
    Garufi, C
    Levi, F
    Aschelter, AM
    Pace, R
    Giunta, S
    Nistico, C
    Galla, DAP
    Silecchia, GF
    Franchi, F
    Narduzzi, C
    Terzoli, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (10) : 1566 - 1571
  • [40] A phase II trial of paclitaxel, cisplatin, and weekly 24 h infusion of 5-Fluorouracil (5-FU)/folinic acid (FA) in patients (pts) with advanced gastric cancer
    Kollmannsberger, C
    Quietzch, D
    Clemens, M
    Lampe, C
    Lingenfelser, T
    Hartmann, JT
    Kanz, L
    Bokemeyer, C
    ANNALS OF ONCOLOGY, 1998, 9 : 48 - 48
12345